Journal of The Korean Society of Inherited Metabolic disease (대한유전성대사질환학회지)

The Korea Society of Inherited Metabolic Disease (대한유전성대사질환학회)
권호 표지

Longterm Benefit and Unmet Needs in Enzyme Replacement Therapy of Gaucher

고셔병 환자에서 효소대체치료의 장기적 효과와 한계

  • Kim, Yoo-Mi (Department of Pediatrics, College of Medicine, Pusan National University Children's Hospital)
  • 김유미 (소아청소년과, 양산 부산대 어린이병원)
  • Published : 2014.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Gaucher disease is a multisystemic disorder arising from a deficient activity of the lysosomal enzyme glucocerebrosidase, which leads to accumulation of glycosylceraide and other glycolipids in the regiculoendothelial system. The characteristics of Gaucher disease are anemia, thrombocytopenia, hepatosplenomegaly, and skeletal disease. Enzyme replacement therapy (ERT) has been proven to prevent progressive manifestations of Gaucher disease and effective in improving anemia, thrombocytopenia, bone markers and biomarkers. However, some patient needs still remain unmet because of the inaccessibility of certain sites including brain, bone and various organs. ERT could not Improve the irreversible lesion such as liver fibrosis, hepatopulmonary syndrome, and necrosis or infarction of bone and other organs. Adult patients with Gaucher disease should be screened for longterm complication such as bone disease, pulmonary hypertension, gallstone, and cancer, especially in patients with splenectomy. Parkinsonism and polyneuropathy was also reported among patients with type 1 Gaucher disease, but ERT does not improve neurological function. We need to review the benefits and unmet needs of ERT in Gaucher disease.

Keywords

References

  1. Brady RO, Kanfer J, Shapiro D. The Metabolism of Glucocerebrosides. I. Purification and Properties of a Glucocerebroside-Cleaving Enzyme from Spleen Tissue. J Biol Chem 1965;240:39-43.
  2. Biegstraaten M, Mengel E, Maródi L, Petakov M, Niederau C, Giraldo P, et al. Peripheral neuropathy in adult type 1 Gaucher disease: a 2-year prospective observational study. Brain 2010;133:2909-19. https://doi.org/10.1093/brain/awq198
  3. Tayebi N, Callahan M, Madike V, Stubblefield BK, Orvisky E, Krasnewich D, et al. Gaucher disease and parkinsonism: a phenotypic and genotypic characterization. Mol Genet Metab 2001;73:313-21. https://doi.org/10.1006/mgme.2001.3201
  4. Charrow J, Andersson HC, Kaplan P, Kolodny EH, Mistry P, Pastores G, et al. Enzyme replacement therapy and monitoring for children with type 1 Gaucher disease: consensus recommendations. J Pediatr 2004;144:112-20 https://doi.org/10.1016/j.jpeds.2003.10.067
  5. Kaplan P, Andersson HC, Kacena KA, Yee JD. The clinical and demographic characteristics of nonneuronopathic Gaucher disease in 887 children at diagnosis. Arch Pediatr Adolesc Med 2006;160:603-8. https://doi.org/10.1001/archpedi.160.6.603
  6. Weinreb NJ, Charrow J, Andersson HC, Kaplan P, Kolodny EH, Mistry P, Pastores G, et al. Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. Am J Med 2002;113:112-9. https://doi.org/10.1016/S0002-9343(02)01150-6
  7. Elstein D, Zimran A. Review of the safety and efficacy of imiglucerase treatment of Gaucher disease. Biologics 2009;3:407-17.
  8. Sims KB, Pastores GM, Weinreb NJ, et al. Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: results of a 48-month longitudinal cohort study. Clin Genet 2008;73:430-40. https://doi.org/10.1111/j.1399-0004.2008.00978.x
  9. Fleurence RL, Iglesias CP, Johnson JM. The cost effectiveness of bisphosphonates for the prevention and treatment of osteoporosis:a structured review of the literature. Pharmacoeconomics 2007;25:913-33. https://doi.org/10.2165/00019053-200725110-00003
  10. Anderson LJ, Henley W, Wyatt KM, Nikolaou V, Waldek S, Hughes DA, et al. Long-term effectiveness of enzyme replacement therapy in children with Gaucher disease: results from the NCS-LSD cohort study. J Inherit Metab Dis 2014 Mar 18.[Epub ahead of print]
  11. Anderson LJ, Henley W, Wyatt KM, Nikolaou V, Hughes DA, Waldek S, Logan S. Long-term effectiveness of enzyme replacement therapy in adults with Gaucher disease: results from the NCS-LSD cohort study. J Inherit Metab Dis 2014 Feb 11.[Epub ahead of print]
  12. Langeveld M, de Fost M, Aerts JM, Sauerwein HP, Hollak CE. Overweight, insulin resistance and type II diabetes in type I Gaucher disease patients in relation to enzyme replacement therapy. Blood Cells Mol Dis 2008;40:428-32. https://doi.org/10.1016/j.bcmd.2007.09.002
  13. Halperin A, Elstein D, Zimran A. Are symptoms of peripheral neuropathy more prevalent in patients with Gaucher disease? Acta Neurol Scand 2007;115:275-8. https://doi.org/10.1111/j.1600-0404.2006.00774.x
  14. Orenstein M, Barbouth D, Bodamer OA, Weinreb NJ. Patients with type 1 Gaucher disease in South Florida, USA: demographics, genotypes, disease severity and treatment outcomes. Orphanet J Rare Dis 2014;9:45. https://doi.org/10.1186/1750-1172-9-45
  15. Sidransky E, Ginns EI, Westman JA, Ehmann WC. Pathologic fractures may develop in Gaucher patients receiving enzyme replacement therapy. Am J Hematol 1994;47:247-9. https://doi.org/10.1002/ajh.2830470325
  16. Ida H, Rennert OM, Kato S, et al. Severe skeletal complications in Japanese patients with type 1 Gaucher disease. J Inherit Metab Dis 1999;22:63-73. https://doi.org/10.1023/A:1005451300167
  17. Taddei TH, Kacena KA, Yang M, et al. The underrecognized progressive nature of N370S Gaucher disease and assessment of cancer risk in 403 patients. Am J Hematol 2009;84:208-14. https://doi.org/10.1002/ajh.21362
  18. Lo SM, Stein P, Mullaly S, Bar M, Jain D, Pastores GM, et al. Expanding spectrum of the association between Type 1 Gaucher disease and cancers: a series of patients with up to 3 sequential cancers of multiple types--correlation with genotype and phenotype. Am J Hematol 2010;85:340-5.
  19. Biegstraaten M, Mengel E, Maródi L, Petakov M, Niederau C, et al. Peripheral neuropathy in adult type 1 Gaucher disease: a 2-year prospective observational study. Brain 2010;133:2909-19. https://doi.org/10.1093/brain/awq198
  20. Lo SM, Liu J, Chen F, Pastores GM, Knowles J, Boxer M, et al. Pulmonary vascular disease in Gaucher disease: clinical spectrum, determinants of phenotype and long-term outcomes of therapy. J Inherit Metab Dis 2011;34:643-50. https://doi.org/10.1007/s10545-011-9313-9
  21. Lachmann RH, Wight DG, Lomas DJ, Fisher NC, Schofield JP, Elias E, et al. Massive hepatic fibrosis in Gaucher's disease: clinico-pathological and radiological features. QJM 2000;93:237-44. https://doi.org/10.1093/qjmed/93.4.237
  22. Bohte AE, van Dussen L, Akkerman EM, Nederveen AJ, Sinkus R, Jansen PL, et al. Liver fibrosis in type I Gaucher disease: magnetic resonance imaging, transient elastography and parameters of iron storage. PLoS One 2013;8:e57507. https://doi.org/10.1371/journal.pone.0057507
  23. Thomas AS, Mehta A, Hughes DA. Gaucher disease:haematological presentations and Complications. Br J Haematol 2014;165:427-40. https://doi.org/10.1111/bjh.12804
  24. Taddei TH, Dziura J, Chen S, Yang R, Hyogo H, Sullards C, et al. High incidence of cholesterol gallstone disease in type 1 Gaucher disease: characterizing the biliary phenotype of type 1 Gaucher disease. J Inherit Metab Dis 2010;33:291-300. https://doi.org/10.1007/s10545-010-9070-1
  25. Peric Z1, Kardum-Skelin I, Puskaric BJ, Letilovic T, Vrhovac R, Jaksic B. An unusual presentation of Gaucher's disease: aortic valve fibrosis in a patient homozygous for a rare G377S mutation. Coll Antropol 2010;34:275-8.
  26. Henderson JM, Gilinsky NH, Lee EY, Greenwood MF. Gaucher's disease complicated by bleeding esophageal varices and colonic infiltration by Gaucher cells. Am J Gastroenterol 1991;86:346-8.
  27. Jones DR, Hoffman J, Downie R, Haqqani M. Massive gastrointestinal hemorrhage associated with ileal lymphoid hyperplasia in Gauchers-disease. Postgrad 1991;67:479-81. https://doi.org/10.1136/pgmj.67.787.479
  28. Lee BH, Kim DY, Kim GH, Cho KJ, Yoon HK, Yoo HW. Progressive mesenteric lymphadenopathy with protein-losing enteropathy; a devastating complication in Gaucher disease. Mol Genet Metab 2012;105:522-4. https://doi.org/10.1016/j.ymgme.2011.12.010